NovaBay ophthalmology study begins in Brazil

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) has begun enrollment of patients in Brazil into its global Phase 2b clinical trial, BAYnovation, investigating Auriclosene ophthalmic solution as a treatment for adenoviral conjunctivitis, a highly contagious form of “pink eye” for which there is no approved treatment. The BAYnovation clinical study is expected to enroll about 450 patients [...]

NovaBay blog post discusses crisis of antibiotic resistance

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) has published a comprehensive discussion on TheChairmansBlog.com, addressing the issue of antimicrobial resistance. TheChairmansBlog.com is an online media publication that enables key executives a unique platform to share insights about their company and industry trends. NovaBay chairman and CEO, Dr. Ron Najafi, explains the history of bacteria and how they have grown [...]

NovaBay’s NVC-422 aganocide renamed auriclosene

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) announced that the World Health Organization has approved the international nonproprietary name (INN) of auriclosene for the company’s lead aganocide compound, NVC-422. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name. Aganocides are NovaBay’s first-in-class topical antimicrobial compounds, which are active against [...]

Galderma and NovaBay begin Phase 2b trial for impetigo

Tweet Galderma S.A. and NovaBay Pharmaceuticals (AMEX:NBY) said on Monday the first patients have been enrolled in their Phase 2b clinical study of a proprietary topical formulation of NovaBay’s NVC-422 for the treatment of impetigo. The study is expected to enroll over 300 patients at 24 clinical sites in four countries and aims to confirm [...]

NovaBay gets additional FDA clearance for NeutroPhase

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has received 510(k) clearance from the FDA to market its NeutroPhase skin and wound cleanser under widened indications, including the moistening and debriding of graft and donor sites. The FDA also cleared NeutroPhase to be administered through a new convenient spray pump. NovaBay is currently seeking appropriate potential partners to out-license [...]

NovaBay aganocides featured in EyeWorld

Tweet In an article in the May issue of EyeWorld, the newsmagazine of the American Society of Cataract and Refractive Surgery, NovaBay Pharmaceuticals (NYSE AMEX:NBY) CEO Dr. Ron Najafi and other members of his ophthalmology team discuss the ability of the company’s topical aganocide compounds to kill bacteria, viruses and fungi without developing drug resistance. Aganocides [...]

NovaBay lands seven new patents

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has received three new composition-of-matter patents in Australia, New Zealand and Mexico, and four Notices of Allowance in Canada, Japan, South Africa and Mexico on its proprietary Aganocide compounds, which includes its lead anti-bacterial and anti-viral, NVC-422. Different topical formulations of NVC-422 are in mid-to-late-stage clinical development in ophthalmology, dermatology and [...]

NovaBay’s Aganocide out-performed antibiotics in study

Tweet NovaBay Pharmaceuticals (AMEX:NBY) says key study data demonstrating that development of resistance to its lead Aganocide compound, NVC-422, is highly unlikely for a variety of infectious organisms, including methicillin-resistant S. aureus (MRSA), compared with traditional antibiotics, were published in the May 2012 issue of Antimicrobial Agents and Chemotherapy, the journal for the American Society [...]